Buffett’s a believer: Berkshire bets $192M on Biogen ahead of key Alzheimer’s filing


Warren Buffett has bet big on Biogen. Buffet’s Berkshire Hathaway bought 648,447 shares of Biogen at a combined worth of $192.4M near the end of 2019, which they disclosed in a recent securities filing.

This comes as a surprise since Buffet isn’t often associated with biotech investments and it could be viewed as a risky move because Biogen is nearing a do-or-die FDA filing for controversial Eisai-partnered Alzheimer’s drug aducanumab.

Read the full article at fiercepharma.com…


Comments are closed.

More in Ashton Tweed Connection
These are the most disruptive companies shaking up healthcare, executives say

Healthcare executives are keeping their eyes on Amazon, but when KLAS Research asked over 300 healthcare leaders to identify the...